UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000001069 |
|---|---|
| Receipt number | R000001238 |
| Scientific Title | Effect of an H2 receptor antagonist or a proton pump inhibitor on prevention of bleeding and healing of the endoscopic submucosal dissection-induced ulceration :a prospective randomized controlled trial |
| Date of disclosure of the study information | 2008/03/10 |
| Last modified on | 2015/12/03 13:35:27 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of an H2 receptor antagonist or a proton pump inhibitor on prevention of bleeding and healing of the endoscopic submucosal dissection-induced ulceration :a prospective randomized controlled trial
Acronym
Effect of an H2 receptor antagonist or a proton pump inhibitor on prevention of bleeding and healing of the endoscopic submucosal dissection-induced ulceration :a prospective randomized controlled trial
Scientific Title
Effect of an H2 receptor antagonist or a proton pump inhibitor on prevention of bleeding and healing of the endoscopic submucosal dissection-induced ulceration :a prospective randomized controlled trial
Scientific Title:Acronym
Effect of an H2 receptor antagonist or a proton pump inhibitor on prevention of bleeding and healing of the endoscopic submucosal dissection-induced ulceration :a prospective randomized controlled trial
Region
| Japan |
Condition
Condition
early gastric cancer,gastric adenoma
Classification by specialty
| Gastroenterology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To compare the effectiveness of H2RA(Roxatidine acetate hydrochloride) with PPI (Lansoprazole) for ESD-induced ulcer against early gastric cancer or gastric adenoma on prevention of bleeding and healing ratio.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Bleeding and healing rario after ESD.
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
NO
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
YES
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Administration of H2RA(Roxatidine acetate hydrochloride) for ESD-induced ulcer
Interventions/Control_2
Administration of PPI (Lansoprazole) for ESD-induced ulcer
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients who were diagnosed as early gastric cancer or gastric adenoma and are considered as the indication of endoscopic submucosal dissection.
Key exclusion criteria
Patients who have anticoagulant or antiplatelet therapy and who cannot stop it.
Target sample size
120
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroyuki Imaeda, M.D., Ph.D. |
Organization
Keio University
Division name
Division of Gastroenterology,Department of Internal Medicine
Zip code
Address
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
TEL
03-3353-1221
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Naoki Hosoe, M.D., Ph.D. |
Organization
Keio University
Division name
Division of Gastroenterology,Department of Internal Medicine
Zip code
Address
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
TEL
03-3353-1211
Homepage URL
hosenao@db3.so-net.ne.jp
Sponsor or person
Institute
Division of Gastroenterology,Department of Internal Medicine, Keio University
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2008 | Year | 03 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2008 | Year | 03 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2008 | Year | 03 | Month | 01 | Day |
Last follow-up date
| 2010 | Year | 06 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2008 | Year | 03 | Month | 07 | Day |
Last modified on
| 2015 | Year | 12 | Month | 03 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001238
